Dr Jose Saro joins Avacta from Roche to lead the Group’s Affimer® therapeutic development strategy and drive the in-house programmes into the clinic
Cambridge, UK, 12 December 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that Dr Jose Saro has been appointed as Chief Medical Officer to lead the Group’s therapeutic development strategy and drive the in-house programmes into the clinic.